Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | PNMT | P11086 | 3/20 | 0.39 |
| ▸ | RORC | P51449 | 11/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406928 | 1.00 | CYP2D6 (0.40) | CYP2D6OPRK1PNMTRORCNPC1 | |
| SCHEMBL6412298 | 0.89 | ALDH1A1 (0.38) | CYP2D6RORCNPC1RAB9AMEN1 | |
| SCHEMBL6407228 | 0.89 | ALDH1A1 (0.38) | CYP2D6RORCNPC1RAB9AMEN1 | |
| SCHEMBL6406276 | 0.87 | PNMT (0.43) | PNMTRORCTDP1ALDH1A1 | |
| SCHEMBL6403549 | 0.87 | PNMT (0.43) | PNMTRORCTDP1ALDH1A1 | |
| SCHEMBL6406107 | 0.85 | GAA (0.47) | PNMTRAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL6406859 | 0.85 | GAA (0.47) | PNMTRAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL6409784 | 0.85 | PNMT (0.43) | PNMT | |
| SCHEMBL6410836 | 0.85 | PNMT (0.43) | PNMT | |
| SCHEMBL6406242 | 0.84 | TSHR (0.38) | NPC1RAB9ATDP1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | G.D. SEARLE & CO. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6822102-B2 | COMPOUNDS SUCH AS (2S,3R)-6,8-DICHLORO-3,4-DIHYDRO-2-(TRIFLUOROMETHYL)-2H-1-BENZOPYRAN-3 -CARBOXYLIC ACID, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC, ANTICARCINOGENIC AGENTS OR ANALGESICS | PHARMACIA CORPORATION | 2004-11-23 | — | — | US | disclosed |
| EP-1274700-B1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | PHARMACIA CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030232844-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders | PHARMACIA CORPORATION | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | PTGS2, PTGES2, PTGER2 | CYP2D6 36/4885OPRK1 302/4885PNMT 2278/4885 |
| US-20030232844-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders | PTGS2, PTGS1, PTGES2 | CYP2D6 31/4885OPRK1 280/4885PNMT 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.